beta-naphthamidine has been researched along with Carcinoma, Lewis Lung in 1 studies
*Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Butler, C; Dorwin, S; Giranda, VL; Hulkower, KI; Klinghofer, V; McGonigal, T; Nienaber, V; Richardson, P; Rockway, T; Sarthy, A; Smith, R; Stewart, K; Weitzberg, M; Wendt, M; Zhao, X | 1 |
1 other study(ies) available for beta-naphthamidine and Carcinoma, Lewis Lung
| Article | Year |
|---|---|
Species specificity of amidine-based urokinase inhibitors.
Topics: Amidines; Amiloride; Amino Acid Sequence; Animals; Antineoplastic Agents; Binding Sites; Blood Proteins; Carcinoma, Lewis Lung; Crystallography, X-Ray; Humans; Mice; Molecular Sequence Data; Naphthalenes; Sequence Alignment; Sequence Homology, Amino Acid; Serine Proteinase Inhibitors; Species Specificity; Thiophenes; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator | 2001 |